» Articles » PMID: 26706615

Early Diagnosis and Monitoring of Mucormycosis by Detection of Circulating DNA in Serum: Retrospective Analysis of 44 Cases Collected Through the French Surveillance Network of Invasive Fungal Infections (RESSIF)

Overview
Publisher Elsevier
Date 2015 Dec 27
PMID 26706615
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

The main objective of this study was to assess the diagnostic performance of a set of three Mucorales quantitative PCR assays in a retrospective multicentre study. Mucormycosis cases were recorded thanks to the French prospective surveillance programme (RESSIF network). The day of sampling of the first histological or mycological positive specimen was defined as day 0 (D0). Detection of circulating DNA was performed on frozen serum samples collected from D-30 to D30, using quantitative PCR assays targeting Rhizomucor, Lichtheimia, Mucor/Rhizopus. Forty-four patients diagnosed with probable (n = 19) or proven (n = 25) mucormycosis were included. Thirty-six of the 44 patients (81%) had at least one PCR-positive serum. The first PCR-positive sample was observed 9 days (range 0-28 days) before diagnosis was made using mycological criteria and at least 2 days (range 0-24 days) before imaging. The identifications provided with the quantitative PCR assays were all concordant with culture and/or PCR-based identification of the causal species. Survival rate at D84 was significantly higher for patients with an initially positive PCR that became negative after treatment initiation than for patients whose PCR remained positive (48% and 4%, respectively; p <10). The median time for complete negativity of PCR was 7 days (range 3-19 days) after initiation of l-AmB treatment. Despite some limitations due to the retrospective design of the study, we showed that Mucorales quantitative PCR could not only confirm the mucormycosis diagnosis when other mycological arguments were present but could also anticipate this diagnosis. Quantification of DNA loads may also be a useful adjunct to treatment monitoring.

Citing Articles

Evaluating the clinical utility of , and bronchoalveolar PCRs for the diagnosis of invasive pulmonary infections in patients with hematological malignancies.

Gali V, Al-Ghanamah R, Finnigan K, Kalchiem-Dekel O, Kamboj M, Hohl T J Clin Microbiol. 2025; 63(2):e0135524.

PMID: 39817757 PMC: 11837534. DOI: 10.1128/jcm.01355-24.


Pulmonary Mucormycosis in an Older Acute Myeloid Leukemia Patient.

Luo B, Tan X, Chen Y, Chen L J Med Cases. 2025; 16(1):23-27.

PMID: 39759161 PMC: 11699860. DOI: 10.14740/jmc5042.


Interlaboratory assays from the fungal PCR Initiative and the Modimucor Study Group to improve qPCR detection of Mucorales DNA in serum: one more step toward standardization.

Rocchi S, Scherer E, White P, Guitton A, Alanio A, Botterel F J Clin Microbiol. 2025; 63(2):e0152524.

PMID: 39745482 PMC: 11837492. DOI: 10.1128/jcm.01525-24.


Application of Metagenomics Next-Generation Sequencing on Diagnosis of Disseminated Infection Caused by in an Acute Lymphoblastic Leukemia Patient.

Chen H, Qiu M, Xu H, Guo P, Peng Y Infect Drug Resist. 2024; 17:5707-5713.

PMID: 39720617 PMC: 11668312. DOI: 10.2147/IDR.S499419.


Mucormycosis.

Czech M, Cuellar-Rodriguez J Infect Dis Clin North Am. 2024; 39(1):121-144.

PMID: 39638718 PMC: 11786989. DOI: 10.1016/j.idc.2024.11.008.